Fused heterocyclic compounds

Details Fused heterocyclic compounds Fused heterocyclic compounds

2007-08-07

2007-08-07

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S070000

Reexamination Certificate

active

10705173

ABSTRACT:
Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.

REFERENCES:
patent: 4115538 (1978-09-01), Satoh et al.
patent: 5049655 (1991-09-01), Vaughan et al.
patent: 5272146 (1993-12-01), Haugwitz et al.
patent: 5436128 (1995-07-01), Harpold et al.
patent: 5441956 (1995-08-01), Vecchietti et al.
patent: 5449766 (1995-09-01), Vaughan et al.
patent: 5457208 (1995-10-01), Portoghese et al.
patent: 5530095 (1996-06-01), Vaughan et al.
patent: 5849708 (1998-12-01), Maratos-Flier
patent: 6033872 (2000-03-01), Bergsma et al.
patent: 6858619 (2005-02-01), Chen et al.
patent: 2003/0023085 (2003-01-01), Chen et al.
patent: 2003/0176694 (2003-09-01), Chen et al.
patent: 2003/0199549 (2003-10-01), Burnett et al.
patent: 0 257 701 (1988-03-01), None
patent: 02 73 4135 (2005-04-01), None
patent: 4-368384 (1992-12-01), None
patent: 2001226269 (2001-08-01), None
patent: WO91/07966 (1991-06-01), None
patent: WO94/07896 (1994-04-01), None
patent: WO95/13071 (1995-05-01), None
patent: WO96/23793 (1996-08-01), None
patent: WO98/31684 (1998-07-01), None
patent: WO99/28492 (1999-06-01), None
patent: WO99/64002 (1999-12-01), None
patent: WO00/15793 (2000-03-01), None
patent: WO00/21577 (2000-04-01), None
patent: WO00/22129 (2000-04-01), None
patent: WO00/39279 (2000-07-01), None
patent: WO00/40725 (2000-07-01), None
patent: WO00/49046 (2000-08-01), None
patent: WO00/49170 (2000-08-01), None
patent: WO00/70347 (2000-11-01), None
patent: WO00/75166 (2000-12-01), None
patent: WO01/05947 (2001-01-01), None
patent: WO01/07606 (2001-02-01), None
patent: WO01/07611 (2001-02-01), None
patent: WO01/21169 (2001-03-01), None
patent: WO01/21577 (2001-03-01), None
patent: WO01/36479 (2001-05-01), None
patent: WO01/68706 (2001-09-01), None
patent: WO01/70975 (2001-09-01), None
patent: WO01/87834 (2001-11-01), None
patent: WO02/02744 (2002-01-01), None
patent: WO02/03070 (2002-01-01), None
patent: WO02/04433 (2002-01-01), None
patent: WO02/06245 (2002-01-01), None
patent: WO02/32897 (2002-04-01), None
patent: WO02/051809 (2002-07-01), None
patent: WO02/057233 (2002-07-01), None
patent: WO02/076929 (2002-10-01), None
patent: WO02/076947 (2002-10-01), None
patent: WO02/083134 (2002-10-01), None
patent: WO02/094799 (2002-11-01), None
patent: WO02089729 (2002-11-01), None
patent: WO03/060475 (2003-07-01), None
patent: PCT/US03/35543 (2004-04-01), None
Berridge, et al. “Inositol Triphosphate, a Novel Second Messenger In Cellular Signal Transduction”, Nature (1984) 312:315-321.
Chambers, et al. “Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1”, Nature (1999) 400: 261-265.
Felley-Bosco, et al. “Constitutive Expression of Inducible Nitric Oxide Synthase in Human Brochial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway”, Am J. Respir Cell. Mol. Biol. (1994) 11: 159-164.
Gonzalez, et al., “alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat”Peptides(1997) 18:387-392.
Gonzalez, et al., “Behavioral Effects of α-MSH and MCH After Central Administration in the Female Rat”Peptides(1996) 17(1):171-177.
Monzon, et al., “Response to Novelty After I.C.V. Injection of Melanin-Concentrating Hormone (MCH) in Rats”Physiol. Behav.(1999) 67(5):813-817.
Offerman, et al. “Gα15and Gα16Couple A Wide Variety of Receptors to Phospholipase C”, The J. of Biological chemistry (1995), 270(25) pp. 15175-15180.
Rai, et al., “Synthesis, P{hysicochemical Properties, and Evaluation of N-Substituted-2-Alkyl-3-Hydroxy-4(1H)-Pyridones” J.. Med. Chem. (1998) 41:3347-3359.
Saito, et al. “Molecular characterization of the melanin-concentrating-hormone receptor”,Nature(1999) 400: 265-269.
Saito, et al., “Melanin-concentrating hormone receptor: an orphan receptor fits the key”Trends Endocrinol. Metab.(2000) 11(8):299-303.
Seyferth, et al., “Some Reactions of Dimethylphosphono-Substituted Diazoalkanes. (MeO)2P(O)CR Transfer to Olefins and 1,3-Dipolar Additions of (MeO)2P(O)C(N2)R1”, J. Org. Chem. (1971) 36(10): 1379-1386.
Shimada, et al., “Mice Lacking melanin-concentrating hormone are Hypophagic and Lean”,Nature(1998) 396: 670-674.
Wilkie, et al., “Characterization of G-Protein α Subunits in the GqClass: Expression in Murine Tissues and In Stromal and Hematopoietic Cell Lines”, Proc. Natl. Acad. Sci. USA (1991) 88: pp. 10049-10053.
Aceto, MD et al., “Dependence studies of new compounds in the Rhesus monkey, rat and mouse”, (1997) Department of Pharmacology and Toxicology, Medical College of Virginia Commonwealth University, pp. 363-407.
Bergman et al., 1980 ACTA Chemica Scandinavica, Series B; Organic Chemistry and Biochemistry B34(10):763-66.
Blechert, S. et al., “Domino reactions—New concepts in the synthesis of indole alkaloids and other polycyclic indole derivatives”, (1995) Insitut Für Organische Chemie, Sekr. C3, Technische Universität Berlin, Straβe des 17 Juni 135, D-10623 Berlin, Germany pp. 592-604.
Boutin et al., (2002) “Melanin-Concentrating Hormone and its Receptors: State of the Art,” Can, J. of Physio. and Pharmacol. 80: 388-395.
Chambers et al., “Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1”Nature,(1999) 400:261-65.
Fujii, H. et al., “A novel abnormal rearrangement in the fishcer indole synthesis”, (1997)Heterocycles45:2109-2112.
Gouyette, A. et al., “Synthesis, DNA intercalation and antitumor activity of9-hdroxy-11-demethylellipticine and some derivatives. Comparison with the corresponding ellipticines”, (1980)Euro. J. Med. Chem.15:503-510.
Guillonneau, C. et al., “Synthesis of 9-O-substituted derivatives of 9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10-and 11-methyl analogues with improved antitumor activity”, (1990)J. Med. Chem.42:2191-2203.
Ishikura et al., “A Novel Entry to Pyrido [4,3-b] Carbazole: An Efficient Synthesis of Ellipticine”, Chemical Abstract, vol. 132, Abstract 237230, 2000.
Jones, RM et al., “5′-Guanidinonaltrindole, a highly selective and potent k-opioid receptor atagonist” (2000)Euro. J. Med. Chem.396:49-52.
Langlois et al., (975) Tetrahedron Letters 11: 955-958.
Lipkowski, AW et al., “Benzomorphan alkaloids: natural peptidomimetics of opioid peptide pharmacophores”, (1995)Letters in Peptide Science,2:177-181.
Olmsted, SL et al., “A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic κ address element to the δ antagonist, naltrindole: 5′-[(N2-alkylamidino)methyl]naltrindole derivatives as a novel class of κ opioid receptor antagonists” (1993)J. Med. Chem.36:179-180.
Portoghese, PS et al., “Naltrindole 5′-isothiocyanate: a nonequilibrium, highly selective δ opioid receptor antagonist” (1990)J. Med. Chem.33:1547-1548.
Portoghese, PS et al., “Design of peptidomimetic δ opioid receptor antagonists using the message-address concept” (1990)J. Med. Chem.33:1714-1720.
Portoghese, PS et al., “Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists”, (1988)J. Med. Chem.31:281-282.
Portoghese, PS et al., “7′-substituted amino acid conjugates of naltrindole. Hydrophillic groups as determinants of selective antagonism of δ1opioid receptor-mediated antinociception in mice.” (1995)J. Med

Affiliated with

Also associated with

Rating

Fused heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3885189